The US FDA has awarded fast track designation to an experimental prostate cancer treatment in clinical trials by the German-based drug maker Bayer.
The treatment is targeted at prostate cancers that have metastasized to the bone, and it involves a delivery system that hits tumors with radium-223 chloride (also referred to as Alpharadin).
Bayer halted a clinical trial of the treatment in June in order to allow those patients in the placebo arm the option to receive the treatment. Bayer is claiming that the treatment leads to patients having a median survival time of 14 months, compared to 11.2 months in the placebo arm.
Sources
Clinical Trial: Phase III ALSYMPCA.
Bayer news release halting ALSYMPCA.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
